AKT1 and prostate carcinoma: To further explore the role of PI3K/Akt/mTOR signaling pathways on the regulation of apoptosis and anti-metastasis in prostate cancer cells in response to Isorhamnetin treatment, both DU145 and PC3 cells were pretreated with PI3K/Akt/mTOR pathway inhibitors (LY294002/deguelin/rapamycin) or Isorhamnetin (20 μM) for 48 h.